What does premature ventricular contractions mean in children?

We now have a certain understanding of ventricular premature beats, but there are many types of ventricular premature beats, and ventricular premature beats in children are one of them. There has also been some medical research on ventricular premature beats in children. So how should ventricular premature beats in children be treated medically? When we go to see a doctor, what common sense will the doctor tell us about this? It is better to seek knowledge on your own than to be told by others. Let’s go and take a look together.

Premature ventricular contraction itself does not cause death. The main concern is the prognostic significance of premature ventricular beats: whether premature beats indicate the development of more serious arrhythmias and whether suppressing premature beats can improve prognosis. For benign ventricular arrhythmias, it has long been known that the prognosis is good.

Ventricular premature beats do not have any adverse prognostic significance, so there is no question of improving survival by controlling this type of premature beat. Traditional concepts about the long-term prognosis of potentially malignant ventricular premature beats are being challenged. Since the CAST trial, it has been recognized that suppressing ventricular premature beats does not always reduce mortality during follow-up.

Some of these drugs, such as class Ic drugs such as encainide, flecainide, and moricizine, while suppressing premature ventricular contractions, doubled the long-term mortality rate compared with the control group. The Class III antiarrhythmic drug amiodarone has been shown in multiple clinical trials to not reduce mortality, and meta-analysis has also shown that it can reduce the risk of death. However, d-sotalol, also a Class III drug, increases mortality. The effect of class II antiarrhythmic drugs, beta-blockers, in inhibiting premature ventricular contractions is not very strong, but several clinical trials have confirmed that beta-blockers can improve the prognosis of patients with myocardial infarction and heart failure, especially reduce the incidence of sudden death.

These materials clearly show that the effects of antiarrhythmic drugs of different classes or different types of the same class on mortality are drug-specific and have no definite correlation with whether or not premature ventricular contractions are suppressed. This view has been increasingly accepted by medical workers.

Most doctors are now studying ventricular premature beats. Although this disease is common, there is no complete cure. We must maintain a good attitude to fight the disease. Sometimes, staying optimistic is also a way to defeat the disease.